{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:56:04Z","timestamp":1787964964934,"version":"build-2784847793"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Scientific research project of Chongqing Medical Biotechnology Association","award":["cmba2022kyym-skxmG006"],"award-info":[{"award-number":["cmba2022kyym-skxmG006"]}]},{"name":"Scientific research project of Chongqing Medical Biotechnology Association","award":["cmba2022kyym-skxmG006"],"award-info":[{"award-number":["cmba2022kyym-skxmG006"]}]},{"name":"Scientific research project of Chongqing Medical Biotechnology Association","award":["cmba2022kyym-skxmG006"],"award-info":[{"award-number":["cmba2022kyym-skxmG006"]}]},{"name":"Scientific research project of Chongqing Medical Biotechnology Association","award":["cmba2022kyym-skxmG006"],"award-info":[{"award-number":["cmba2022kyym-skxmG006"]}]},{"name":"Scientific research project of Chongqing Medical Biotechnology Association","award":["cmba2022kyym-skxmG006"],"award-info":[{"award-number":["cmba2022kyym-skxmG006"]}]},{"name":"Decision Consultation Management Innovation Project of Shapingba District","award":["Jcd202278"],"award-info":[{"award-number":["Jcd202278"]}]},{"name":"Decision Consultation Management Innovation Project of Shapingba District","award":["Jcd202278"],"award-info":[{"award-number":["Jcd202278"]}]},{"name":"Decision Consultation Management Innovation Project of Shapingba District","award":["Jcd202278"],"award-info":[{"award-number":["Jcd202278"]}]},{"name":"Decision Consultation Management Innovation Project of Shapingba District","award":["Jcd202278"],"award-info":[{"award-number":["Jcd202278"]}]},{"name":"Decision Consultation Management Innovation Project of Shapingba District","award":["Jcd202278"],"award-info":[{"award-number":["Jcd202278"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00432-023-04775-2","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:01:40Z","timestamp":1684202500000},"page":"9213-9219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"149","author":[{"given":"Xianghua","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinli","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huakan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"4775_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561","journal-title":"Front Pharmacol"},{"key":"4775_CR2","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541\u20133543","journal-title":"J Clin Oncol"},{"key":"4775_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.mric.2014.04.008","volume":"22","author":"CP Corona-Villalobos","year":"2014","unstructured":"Corona-Villalobos CP, Zhang Y, Zhang WD, Kamel IR (2014) Magnetic resonance imaging of the liver after loco-regional and systemic therapy. Magn Reson Imaging Clin N Am 22:353\u2013372","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"4775_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.601240","volume":"10","author":"C Donisi","year":"2020","unstructured":"Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M (2020) Immune checkpoint inhibitors in the treatment of HCC. Front Oncol 10:601240","journal-title":"Front Oncol"},{"key":"4775_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905","journal-title":"N Engl J Med"},{"key":"4775_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE\u2014version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (engl Ed) 112:90\u201392","journal-title":"Actas Dermosifiliogr (engl Ed)"},{"key":"4775_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1568009619666191114110359","volume":"20","author":"F Gao","year":"2020","unstructured":"Gao F, Yang C (2020) Anti-VEGF\/VEGFR2 monoclonal antibodies and their combinations with PD-1\/PD-L1 inhibitors in clinic. Curr Cancer Drug Targets 20:3\u201318","journal-title":"Curr Cancer Drug Targets"},{"key":"4775_CR8","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.7150\/ijbs.70691","volume":"18","author":"H Jin","year":"2022","unstructured":"Jin H, Qin S, He J, Xiao J, Li Q, Mao Y, Zhao L (2022) New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. Int J Biol Sci 18:2775\u20132794","journal-title":"Int J Biol Sci"},{"key":"4775_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, Matsuoka Y, Ghosh S, Kitano H, Nomoto K, Matsui J, Funahashi Y (2019) Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS\u00a0One 14:e0212513","journal-title":"PLoS\u00a0One"},{"key":"4775_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"4775_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6","journal-title":"Nat Rev Dis Primers"},{"key":"4775_CR12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","volume":"25","author":"MA Morse","year":"2019","unstructured":"Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS (2019) The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res 25:912\u2013920","journal-title":"Clin Cancer Res"},{"key":"4775_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J (2021) Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol 22:977\u2013990","journal-title":"Lancet Oncol"},{"key":"4775_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro B, Sarobe P, Herv\u00e1s-Stubbs S, Melero I (2021) Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 18:525\u2013543","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4775_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207132","volume":"13","author":"A Shlomai","year":"2018","unstructured":"Shlomai A, Leshno M, Goldstein DA (2018) Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PLoS\u00a0One 13:e0207132","journal-title":"PLoS\u00a0One"},{"key":"4775_CR16","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fimmu.2020.01956","volume":"11","author":"Y Song","year":"2020","unstructured":"Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B (2020) Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol 11:1956","journal-title":"Front Immunol"},{"key":"4775_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/19420862.2019.1654303","volume":"11","author":"J Wang","year":"2019","unstructured":"Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, Ni H, Chen B, Xiong Y, Liu Y, Peng B, Yu D, Jiang H, Liu J (2019) Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. Mabs 11:1443\u20131451","journal-title":"Mabs"},{"key":"4775_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, Liu J, Ren Z, Xiong J, Mao X, Zhang L, Yang J, Li L, Chen X, Wang Z, Gu K, Chen X, Pan Z, Ma K, Zhou X, Yu Z, Li E, Yin G, Zhang X, Wang S, Wang Q (2021) Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized open-label, phase II trial. Clin Cancer Res 27:1003\u20131011","journal-title":"Clin Cancer Res"},{"key":"4775_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A (2019) Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer 18:60","journal-title":"Mol Cancer"},{"key":"4775_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K (2022) Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer 21:28","journal-title":"Mol Cancer"},{"key":"4775_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.14218\/JCTH.2017.00059","volume":"6","author":"S Young","year":"2018","unstructured":"Young S, Taylor AJ, Sanghvi T (2018) Post locoregional therapy treatment imaging in hepatocellular carcinoma patients: a literature-based review. J Clin Transl Hepatol 6:189\u2013197","journal-title":"J Clin Transl Hepatol"},{"key":"4775_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","volume":"24","author":"X Yue","year":"2021","unstructured":"Yue X, Li Y, Wu J, Guo JJ (2021) Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Reg Issues 24:1\u20135","journal-title":"Value Health Reg Issues"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04775-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:02:21Z","timestamp":1744160541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04775-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4775"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04775-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"2 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared that they had no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}